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Abstract
Background: Cerebral microbleeds, visible on gradient-recalled echo (GRE) T2* MRI, have generated increasing interest as
an imaging marker of small vessel diseases, with relevance for intracerebral bleeding risk or brain dysfunction.
Methodology/Principal Findings: Manual rating methods have limited reliability and are time-consuming. We developed a
new method for microbleed detection using automated segmentation (MIDAS) and compared it with a validated visual
rating system. In thirty consecutive stroke service patients, standard GRE T2* images were acquired and manually rated for
microbleeds by a trained observer. After spatially normalizing each patient’s GRE T2* images into a standard stereotaxic
space, the automated microbleed detection algorithm (MIDAS) identified cerebral microbleeds by explicitly incorporating
an ‘‘extra’’ tissue class for abnormal voxels within a unified segmentation-normalization model. The agreement between
manual and automated methods was assessed using the intraclass correlation coefficient (ICC) and Kappa statistic. We
found that MIDAS had generally moderate to good agreement with the manual reference method for the presence of lobar
microbleeds (Kappa=0.43, improved to 0.65 after manual exclusion of obvious artefacts). Agreement for the number of
microbleeds was very good for lobar regions: (ICC=0.71, improved to ICC=0.87). MIDAS successfully detected all patients
with multiple ($2) lobar microbleeds.
Conclusions/Significance: MIDAS can identify microbleeds on standard MR datasets, and with an additional rapid editing
step shows good agreement with a validated visual rating system. MIDAS may be useful in screening for multiple lobar
microbleeds.
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Introduction
Over the last decade, the use of iron-sensitive MRI sequences
(including Gradient Echo [GRE] T2*-weighted imaging and
susceptibility-weighted imaging) has increased in many clinical
settings, including acute stroke units and clinics. This has led to the
improved detection of cerebral microbleeds (CMBs) and other
forms of intracranial haemorrhage. Cerebral microbleeds are
small, rounded areas of homogeneous low signal visualized on
GRE T2*-weighted images because haemosiderin (a paramagnetic
product of blood degradation) has high magnetic susceptibility,
causing local field inhomogeneities and signal loss. Cerebral
microbleeds are due to perivascular bleeding from small vessels
affected mainly by hypertensive vasculopathy and cerebral
amyloid angiopathy [1]. Cerebral microbleeds are increasingly
found in elderly subjects and patients with cerebrovascular disease,
raising many important questions: Are patients with CMBs at
increased risk of intracerebral haemorrhage? Do CMBs cause
brain dysfunction? Are they a useful diagnostic marker for cerebral
amyloid angiopathy (CAA)? CMBs are also found frequently in
traumatic brain injury and may be a useful marker for diffuse
axonal injury with potential relevance for prognosis [2]. To tackle
these questions, it is important to reliably detect and map CMBs.
The current reference standard method for microbleed
identification is based on the manual definition of abnormal brain
tissue using visual rating scales, which is laborious, operator-
dependent and time-consuming, with limited intra-rater and inter-
rater reliability [3]. Furthermore, manual rating does not easily
allow the comparison of the spatial distribution of microbleeds
between individuals or groups, which may be crucial in assessing
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of the many CMB ‘‘mimics’’ with similar signal and morphological
characteristics, and the unpredictable, widespread distribution of
CMBs in the brain, automatic identification is challenging.
Moreover, standard clinical GRE MRI inherently has limited
tissue contrast and is very sensitive to susceptibility artefacts from
field inhomogeneities; the modest standard field strength (1.5T),
thick slices and non-isotropic voxels, may further reduce the
conspicuity and size of some microbleeds [3].
An ideal automated CMB rating method should: (1) reliably
detect CMBs; (2) be able to do so given standard clinical images;
(3) be simple to use, and less time consuming than manual
methods; and (4) should map CMBs in a common stereotactic
space. We propose a new procedure for microbleed detection
using automated segmentation (MIDAS), which explicitly incor-
porates an ‘extra’ tissue class for abnormal voxels within a unified
segmentation-normalization model [5,6]. The performance of
MIDAS is assessed here on a real dataset of standard clinical MR
images from 30 stroke patients.
Results
Here, we turn to the performance of MIDAS in detecting
CMBs across a range of 30 unselected patients with known CMB
status based on manual identification by an expert, considered
here as the reference standard to define the true positives. In the
manual identification, the presence, number and anatomical
distribution of CMBs was rated using the validated Microbleed
Anatomical Rating Scale (MARS) [3]. The data used here were
previously acquired with a standard clinical protocol and thus
were not prospectively optimised for MIDAS. For more details, see
the Materials and Methods section below.
Figure 1 illustrates CMBs identified in six representative
patients using MIDAS. Our method clearly identified these
CMBs, of variable sizes and located in different brain regions
(Figure 1).
The results can be summarised by the following key points.
First, MIDAS was much more successful for detecting CMBs in
lobar regions than infratentorial or deep regions (detailed results in
each patient are provided in the tables in Supplementary Material
S1). Specifically, across the 22 patients who have lobar CMBs, 17
patients were identified by the automated method. A close look at
the 5 unsuccessful cases revealed that all of them have only a single
CMB (cases 2, 8, 14, 17 and 28; see Supplementary Material S1).
Thus, if we consider whether a patient has a single or multiple
CMBs, we found that MIDAS identified 8 out of 13 patients (62%)
who have a single CMB but successfully identified all 9 patients
who have 2 or more CMBs (100%).
Second, some CMBs were missed by MIDAS, predominantly in
two situations (Figure 2A): (i) lesions located within our artefact
mask, predefined within MIDAS as a map of potential artefacts
(see Materials and Methods section below), and thus rejected from
the final output images (see example of a CMB in the right
cerebellum, column 1 Figure 2A); and (ii) small CMBs with low
contrast from their background, probably caused by partial
volume effects due to the thick slices of our clinical T2* images
(see columns 2 and 3 of Figure 2A).
Despite the morphological procedures applied here in cleaning
up the output images (see Materials and Methods section below),
the resulting maps may still contain a few artefacts. These consist
of regions of low signal intensity that mimic CMBs, of three types:
(i) most frequently at the edges of brain regions (air-bone
susceptibility effects) – these include the inferior temporal,
orbitofrontal and posterior fossa regions (see columns 1 and 2 of
Figure 2B); (ii) low signal within other abnormalities in the brain
such as infarcts (column 3 of Figure 2B); and (iii) flow voids in
blood vessels (column 4 of Figure 2B). However, these artefacts
were easily removed using a ‘‘semi-automated’’ approach, i.e. by
(manually) excluding the obvious artefacts from the final maps.
These obvious artefacts, in particular those of type (i) at the edges
of brain regions, were excluded by a trained observer (MAK) and
were seen in 12 patients (see the tables in Supplementary Material
S1 for more details).
The Kappa coefficient for agreement between MIDAS and the
reference standard manual identification (MARS) in patients who
had one or more CMBs in lobar regions was 0.43, increasing to
0.65 using the semi-automated approach. The intraclass correla-
tion coefficient for agreement about CMB count in lobar regions
using MIDAS in comparison to MARS was 0.71, increasing to
0.87 when using the semi-automated method. The Kappa
coefficient of identifying patients with two or more lobar CMBs
increased to 0.74 using the semi-automated approach.
Discussion
We present here a new method of identifying CMBs (MIDAS).
To the best of our knowledge, this is the first (semi-)automated
method developed for detecting and mapping CMBs on standard
clinical images which are routinely available in many stroke clinics.
Our method has several important advantages over purely manual
rating: first, it eliminates intra- and inter-rater reliability; second, it
is less laborious, and thus more practical for analyzing large
datasets; third, MIDAS can generate detailed lesion maps in a
standard coordinate space, making group analyses and correlation
with clinical, behavioural or genetic data straightforward; fourth, it
can automatically quantify additional spatial characteristics,
including CMB location, size, and shape; fifth, the algorithm is
flexible and can potentially incorporate other type of images with
different contrasts and resolution. A final advantage is that the
software in which our method is implemented is freely available
(see Materials and Methods below).
In comparison with a validated visual rating scale (MARS),
MIDAS has shown generally moderate to good agreement for the
presence of lobar CMBs (Kappa 0.43, improved to 0.65 using the
semi-automated method), which compares favourably with
previous manual methods showing inter-observer Kappa values
in the range of 0.33 to 0.88 [7]. Agreement about the number of
CMBs was very good for lobar regions. Of note, our method
successfully identified all patients with multiple (.1) CMBs: this
may be important because multiple CMBs on standard GRE T2*
sequences may be of more significance than a single lesion; it has
also been suggested that only patients with more than one CMB be
included in research studies, to maximize the reliability of ratings
[3,7]. The inclusion of patients judged to have a single CMB
substantially reduces the inter-rater reliability of CMB identifica-
tion, suggesting that raters find it most difficult to reliably decide
whether one CMB or no CMBs are present. Because reliability is
critical for any useful clinical or research tool, we investigated the
ability of MIDAS to identify the group of patients with 2 or more
CMBs. There are also biological grounds to suggest that multiple
CMBs are of greater significance than a single lesion: for example,
a recent prospective study of stroke patients [8] showed that a
single CMB did not substantially increase the risk of ischaemic
stroke or fatal intracranial haemorrhage; whilst having 2 or more
CMBs did have prognostic relevance for these outcomes [8]. Thus,
MIDAS could be used in a clinical or research setting to rapidly
screen patients for ‘‘multiple lobar CMBs’’, a group potentially of
clinical importance with regard to diagnosing cerebral amyloid
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haemorrhage in patients taking antithrombotic drugs [8,10].
We now discuss the potential factors that may explain the
moderate agreement between the fully automated MIDAS and the
manual identification using MARS. First, it is worth noting
MIDAS was tested here on relatively challenging clinical data that
were acquired using standard T2* sequences at 1.5T. Specifically,
with a slice thickness of 5.0 mm and a gap of 1.5 mm, partial
volume effects can have a strong impact on the T2* signal
distribution when using the unified spatial normalisation in
MIDAS that involved data smoothing and re-slicing [5], and
may thus hinder the detectability of CMBs. These partial volume
effects can explain why a few (tiny) CMBs have been missed by
MIDAS on these datasets (as illustrated in Figure 2A). Second, the
manual method (MARS) was applied on native (unresliced) images
that had better in-plane resolution and were not smoothed or re-
sliced, whereas MIDAS mapped all CMBs on the final normalised
(re-sliced) images. Third, MIDAS operated in a monospectral
mode using GRE T2* images only, whereas in the manual method
clinicians were allowed to use other available images if needed to
identify CMB mimics (e.g. [1]). Although this may introduce a bias
in favour of the manual method, we preferred here to compare
MIDAS to the manual method as commonly practiced in the
clinical setting. On the other hand, we did not incorporate these
additional images within the modified unified segmentation
framework (for instance in a multispectral mode) because of the
spatial distortion and signal loss in the T2* images that make the
co-registration (voxel-to-voxel mapping) between the different
images particularly challenging.
Future iterations of our technique should substantially improve
its performance. For example, use of a predefined artefact mask by
removing all regions with expected artefacts, might increase the
specificity of our method for CMBs in deep and infratentorial
regions. Importantly, the flat prior used here for CMBs (see
Materials and Methods section) can potentially be further
optimised if additional knowledge about the regional prevalence
of CMBs is available (e.g. [11]); for instance by increasing the prior
CMB probability in vulnerable regions and decreasing it in less
likely regions. Furthermore, a systematic investigation of the
impact of the different thresholds used here, including thresholds
on posterior probabilities and size of CMBs, would help in
optimizing the thresholds for specific applications more objective-
ly. Future applications could also extend the analysis to include
other imaging modalities/contrasts to better distinguish genuine
CMB from their mimics.
It is premature to conclude that MIDAS should substitute
manual methods for diagnosis or screening for CMBs in clinical
practice. Further improvements are needed before we can
recommend its routine clinical use. The limitations of MIDAS
were particularly noted for patients with a single CMB (here 5 out
of 13 patients with a single CMB were missed) and when using
non-optimised data acquisition protocols (the output in 12
segmented patients contained some artefacts/mimics). Neverthe-
less, the semi-automated method with manual editing substantially
improves the performance of MIDAS even on standard clinical
images. For instance, to assist clinicians and speed up the detection
of CMBs, it is possible to use the output from MIDAS as a starting
map and then clinicians can manually alter it by either adding any
missed CMBs or deleting any mimics. Manual editing using a
semi-automated method has been shown to be an attractive
alternative to time-consuming fully manual methods in various
fields, including for instance multiple sclerosis [12,13].
Figure 1. MIDAS detection in 6 different patients with variable numbers and locations of cerebral microbleeds. Typical T2* axial slices
are shown with a zoom (white rectangle) on the region with successfully identified cerebral microbleed(s).
doi:10.1371/journal.pone.0017547.g001
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the reference standard of a validated rating scale, we anticipate
that it will be even more successful when applied to research-
optimised data, including for instance isotropic voxels with thin
slices and high in-plane resolution [14]), optimized contrast for
CMB detection (e.g. susceptibility-weighted imaging [SWI] [15]),
or higher magnetic field strength [14,16].
In conclusion, this study has demonstrated a new semi-
automated CMB detection method (MIDAS), which can be useful
for CMB rating on standard clinical MR datasets. This method
has particular promise in: (i) fast screening of patients for multiple
lobar CMBs, and (ii) locating CMBs in stereotaxic space, which is
useful for producing group lesion overlap maps. We plan to use
this method to investigate spatially sensitive hypotheses concerning
the relationship between CMBs and clinical measures, including
cognitive impairment. However, further improvements in the
method presented here are necessary in order to increase its
performance for clinical applications.
Materials and Methods
Subjects
We considered unselected, consecutive patients admitted to the
Stroke Service at the National Hospital for Neurology and
Neurosurgery (NHNN). Our stroke service takes all suspected
stroke patients admitted from the surrounding district and has a
policy of performing MRI with GRE T2* sequence in all of them
unless there is a contra-indication (e.g. too medically unstable,
Figure 2. Missed cerebral microbleeds and artefacts. (A) example of missed cerebral microbleeds when using MIDAS (false negatives). (B)
example of some remaining artefacts that resisted the clean-up step in MIDAS (false positives).These false positives are easily and quickly identified in
a final manual editing step.
doi:10.1371/journal.pone.0017547.g002
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have an MRI or with poor quality images (e.g. due to motion
artefact) were excluded (30% of all patients presenting to our
clinical service). The first 30 consecutive eligible patients (mean
age 69 years, range 21–83 years, 14 males, 16 females) with
definite or probable microbleeds on GRE T2* sequences were
included (images were rated manually by an experienced
observer [SMG] using the Microbleed Anatomical Rating Scale
[3]). Using MARS, microbleeds were detected in 28% of our
population.
We also included a control group of 44 subjects (mean age 52
years, range 21–83 years, 23 males, 21 females) referred to the
Stroke Service over the same time period, who had an entirely
normal MRI study (reported by a consultant neuroradiologist and
checked by an experienced observer [SMG] as having no CMBs
or any other imaging evidence of cerebrovascular disease). The
data from these controls is not essential for the automated
algorithm, but was used here to generate a map of potential
artefacts (false positives) to be excluded from the output images
(see below).
The study was approved by the National Hospital for
Neurology and Neurosurgery Research Ethics Committee.
Data acquisition
MRI acquisitions were carried out at 1.5 Tesla on a GE
EchoSpeed system (General Electric, Milwaukee, WI, USA) using
a standardized protocol, between 2004 and 2007. Each subject
had axial T2-weighted Fast Spin Echo (TR=6000 ms, TE=
105 ms, matrix=2566224, field-of-view=24618 cm, slice thick-
ness=5 mm, slice gap=1.5 mm, voxel size=0.93860.93866.5
mm
3, NEX2) and axial T2*-weighted gradient echo GRE
(TR=300 ms, TE=40 ms, flip angle=20u, field-of-view=246
18 cm, slice thickness=5 mm, slice gap=1.5 mm, voxel size=
0.93860.93866.5 mm
3, acquisition time 2 min).
Microbleed Detection by Automated Segmentation
(MIDAS)
All analyses were carried out with scripts written in Matlab (The
MathWorks, Natick, MA, USA) that incorporated processing
functions of the statistical parametric mapping (SPM8) software
package (Wellcome Trust Centre for Neuroimaging, London, UK,
http://www.fil.ion.ucl.ac.uk/spm/).
The first step is to spatially transform or ‘‘normalize’’ each
patient’s brain images into a standard space; we used that defined
by the Montreal Neurological Institute (MNI) [17]. This spatial
transformation is based on the unified probabilistic normalisation-
segmentation framework that combines image registration, tissue
classification, and bias correction as implemented in SPM8 [5],
with two major modifications: (i) it incorporates some constrains
on the mixture of Gaussians used to model the T2*-weighted
image intensities, and (ii) it considers CMBs as an unexpected and
atypical tissue class that can explicitly be modelled within the
probabilistic framework as an extra class with an iteratively
optimised empirical prior (for more details see [6]). The output
of this modified normalisation-segmentation method produces six
separate probabilistic images, one for each tissue class (Figure 3B
and 4A): i) normal brain, a mixture of grey and white matter
(GWM); ii) cerebrospinal fluid (CSF); iii) CMBs; iv) ‘‘skull’’ and
other low intensities around the brain; v) ‘‘scalp’’; and, vi)
background (other).
The initial iteration of the unified normalisation-segmentation
procedure uses some modified priors and constrained mixture of
Gaussians; producing a ‘‘first pass’’ of the empirical prior which,
unlike the modified priors, is subject-specific. This subject-specific
prior is optimised (i.e. cleaned up) using morphological operations
on the output tissue class form the first step. This included
binarisation, granulometry and masking applied on the output
tissue class to reduce false positives (see pages 23 and 318 of Ref.
[18]). The optimised prior is then included in a second iteration of
the unified normalisation-segmentation procedure. The output is
an image that codes the degree of abnormality at each voxel.
Additional thresholds (on both size and height) are then used to
generate a binary map that visualises CMB localisation and extent.
1. Constrained mixture of Gaussians. The mixture of
Gaussians used in the unified normalisation-segmentation
procedure incorporates a smooth intensity variation and
nonlinear registration with tissue priors [5]. The priors on the
tissue class are encoded by deformable tissue probability maps
generated from the averages of affine registered and tissue
classified images of 452 subjects (http://www.loni.ucla.edu/
ICBM/). These maps, in MNI space, represent the probabilities
of finding GM, WM, and CSF tissues at each voxel. We also
considered additional priors as implemented in the new
segmentation toolbox of SPM8, which have been optimised for
segmenting high resolution anatomical images (e.g. T1-weighted)
of normal brains. The first challenge was to adapt these priors to
the signal distribution in our T2*-weighted images. As illustrated
in Figure 3A, the distribution of T2*-intensities has a rather poor
differentiation between brain tissues, which has direct implications
on the optimal choice of priors:
(i) GM and WM voxels appear at comparable intensities
within a similar range. For this reason, the prior for coding
GM and WM voxels was approximated by the sum of GM
and WM priors (as one class noted GWM in Figure 3B).
This is reasonable as the correct classification between gray
and white matter voxels is not critical when using T2*-
images at low spatial resolution.
(ii) In order to model high signal values of the CSF in the
ventricles and around the cortex, an explicit CSF prior was
included (CSF in Figure 3B).
(iii) Because there is maximal uncertainty about the a priori
spatial locations of CMBs, that is, they may appear
anywhere in the brain [1,19], a flat prior was used (CMB in
Figure 3B). This was constructed by having non-null values
(e.g. prior=0.1) inside the brain and zeros outside the
brain. It models all voxels that cannot be considered as
‘‘normal’’ in the mixture of Gaussians algorithm (similar to
the ‘‘rejection class’’ principle suggested by previous work
[20]). This is the empirical prior that is optimised
iteratively in the next steps.
(iv) To take into account low signal intensity voxels around the
brain (i.e. the skull) that might be similar to the intensities
of interest in CMBs, a fourth tissue probability map
(‘‘skull’’ in Figure 3B) was explicitly included.
(v) The soft tissue outside the cortex with relatively high
intensities (e.g. scalp and eyes) was modelled with an
additional tissue probability map (‘‘scalp’’ in Figure 3B).
(vi) All voxels outside the subject’s head (air/background) were
explicitly modelled with another prior (noted ‘‘other’’ in
Figure 3B); this is included by default in the unified
segmentation procedure of SPM8 [5].
The unified normalisation-segmentation model combines tissue
class, intensity bias and nonlinear warping into the same
probabilistic models that are assumed to generate subject-specific
images (see equation (14) in [5]). Hence, it was critical to ensure
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intensities of the tissue class expected at the locations coded in the
priors. Following an initial test of the algorithm (results not shown
here), we implemented two empirical constrains on the mixture of
Gaussians during the optimisation of its parameters using the
Expectation-Maximisation algorithm. This was to minimise the
impact of low contrast, partial volume in the thick slices and
possible spatial distortions. We achieved this by forcing the mean
of the Gaussians (equation (23) in [5]) for (i) CSF tissue to be
higher than the mean of Gaussians of GWM (right-side to the
dashed line of the histogram in Figure 3A), and (ii) CMBs to be less
than the 50% of the mean of Gaussians of GWM (i.e. forcing the
search for CMBs in the left-side to the dashed line of the histogram
in Figure 3A).
All six priors were sampled to an isotropic 1.5 mm resolution.
The unified model used the following number of Gaussians
(3,2,2,3,2, and 4) to model each of the intensity distributions of
GWM, CSF, CMBs, ‘‘skull’’, ‘‘scalp’’ and the ‘‘other’’ tissues
respectively. The rest of the normalisation-segmentation param-
eters were identical to our previous work (see for more details [6]).
2. Optimisation of the empirical prior. The initial unified
normalisation-segmentation on the index patient data resulted in
different tissues classes which corresponded with the expected
tissues, including the CMB class (Figure 4A). This image contained
all the CMBs identified by an experienced rater for this patient.
However, it also contained some artefacts (false positives)
mimicking CMBs that needed to be removed. These artefacts
were misclassified because their T2* intensities were comparable
to CMBs (arrows in Figure 4B). These ‘‘mimics’’ include
calcification or iron deposits in the basal ganglia, dentate nuclei,
substantia nigra, and brainstem; flow voids of cerebral vessels and
air/bone susceptibility artefacts particularly at the edges of the
frontal or temporal lobes, or cerebellum.
To minimise false positives we used the following morphological
operations [18]. First, the CMB class was converted to a binary
image using a 0.2 probability threshold. Second, we set an upper
limit for the size of a cerebral microbeed to differentiate them from
‘‘macrobleeds’’ (e.g. lobar haemorrhage). We set an upper
diameter limit for a CMBs of 8 mm; a previous study suggests
that intracerebral haemorrhage volume (at least in CAA) has a
Figure 3. Illustrations of T2* signal intensity histogram and tissue priors. (A) histogram of typical T2* intensities in a patient with multiple
cerebral microbleeds. The unit of T2* intensity is arbitrary. The dashed line indicates the mean intensity of gray and white tissue voxels. (B) Illustration
of the 6 tissue priors used in MIDAS during the first iteration of unified normalisation-segmentation. GWM=gray and white matter,
CSF=cerebrospinal fluid, CMB=cerebral microbleeds.
doi:10.1371/journal.pone.0017547.g003
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[7,21,22]. In order to take into account possible partial volume
effects, we used a cut-off volume of 0.675 cm
3 corresponding to a
cylinder of maximum 2-slices high by 8 mm diameter. All regions
with larger volumes (.0.675 cm
3) assessed by morphological
granulometry (see pages 318–327 of Ref. [18]) were excluded. It is
also possible to introduce a lower limit for the size of CMBs in
order to match the thresholds used in the manual procedure (see
below). To do that, only CMBs that are at least two contiguous
voxels in size were considered (i.e. single voxel CMBs (volu-
me,0.006 cm
3), if any, were excluded). Third, all regions of the
‘‘skull’’ class, including the artificial hypointensities around the
cortex (e.g. air-bone susceptibility effects at the skull base), were
used as a mask and removed from the CMB class. Fourth, because
we were not interested in hypointenisties within CSF, we excluded
all voxels and their nearest neighbours that showed a reasonably
high probability (.0.5) of being in the CSF tissue class. Finally, we
created an additional mask of irrelevant voxels by including all
voxels that had been identified as false positive CMBs (e.g. from
basal ganglia calcification [23] or air-bone susceptibility artefacts)
in any of our 44 healthy controls. This was achieved by running
the whole automated procedure on each healthy control separately
using the same parameters and then grouping any identified voxels
as CMBs in one map (that we referred to as the artefact mask).
Note that air-bone susceptibility effects were the dominant source
of artefacts (false positives) over our 44 controls, in particular at the
edges of the inferior temporal, orbitofrontal and posterior fossa
regions. Hypointense areas in patients classified as CMBs by our
method were discarded if they overlapped with this artefact mask.
These different morphological operations (i.e. binarisation,
granulometry and masking) were hard-coded by default in our
method and produced a refined image of the CMB class (see
schematic illustration of all steps in Supplementary Material S1).
3. Unified normalisation-segmentation: second iteration.
The refined version of the CMB class was then used with the
other unchanged classes (GWM, CSF, ‘‘skull’’, and ‘‘scalp’’)
as new priors for unified normalisation-segmentation of the
original T2*-weighted image. This second iteration was more
specific for identifying true CMBs (Figure 5), as the influence
of artificial hypointensities had been minimised. The identified
hypointensities appeared as continuous probability values in
the CMBs class varying from 0 to 1 (Figure 5 middle row); these
values represent the likelihood that a voxel is part of a CMB
rather than one of the other four tissue classes. It is possible to
threshold this image to generate a binary CMB map (example
with CMBs shown in red, lowest row Figure 5, using typically a
threshold of 0.5), and calculate both their exact location in
stereotaxic MNI space, and volume (not shown).
MIDAS takes less than 3 minutes to run per patient (PC 64-bit,
3.2 GHz Intel CPU, 12 GB RAM). An additional 5–10 minutes
Figure 4. Illustrations of typical first iteration outputs. (A) output of the first iteration on typical T2*-images of a patient with multiple
microbleeds (white arrows). (B) illustration of typical artefacts (white arrows) that are later removed in MIDAS.
doi:10.1371/journal.pone.0017547.g004
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manually exclude the obvious artefacts that were seen in some
patients (see Results section above).
Manual identification of cerebral microbleeds: reference
standard
The GRE T2*-weighted MRI images were displayed in semi-
dark conditions using an Agfa IMPAX PACS system, and assessed
manually by a clinical neurologist (SMG) who was trained in CMB
rating by an experienced consultant neuroradiologist (HRJ). The
presence, number and anatomical distribution of CMBs was rated
using the validated Microbleed Anatomical Rating Scale (MARS)
[3]. The rater was blinded to clinical data and the results of
automatic CMB detection procedure. Definite CMBs were defined
as small, rounded or circular, well-defined hypointense lesions
within brain parenchyma with clear margins raging from 2 mm to
10 mm in size. Care was taken to exclude all CMB mimics using
all available imaging, including axial T2-weighted fast spin echo
images that were acquired in the same session as the GRE T2*
images. In particular, flow voids in blood vessels were excluded by
their location in cerebral sulci, their visibility on the T2-weighted
images, and their lack of ‘‘blooming’’ on T2*-weighted images.
The inter-rater agreement for the presence of definite CMBs
identified in any brain location using MARS was kappa=0.68 [3].
The manual identification is considered here as the reference
standard to define the true positives. All identified abnormalities
from MIDAS were classified by a trained observer (MAK) as true
positives or false positives (artefacts), without reference to the
manual ratings. Cases of uncertainty (in 5 patients) were decided
by consensus (MAK and DJW). Agreement between the manual
and the automated method was assessed by the intraclass
correlation coefficient (ICC) and Kappa statistics [24], either over
the whole brain or in separate brain regions (e.g. lobar versus
deep/infratentorial). The interpretation of Kappa values was
Figure 5. Illustration of genuine cerebral microbleeds. Top: axial T2*-weighted slices at different z-coordinates. Middle: final output images
from the second iteration of MIDAS showing the microbleeds identified in white. Bottom: visualisation of the same cerebral microbleeds in red on a
white background whole-brain mask.
doi:10.1371/journal.pone.0017547.g005
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.0.8 for poor, fair, moderate, good and excellent respectively (see
Table II of ref. [25]). All post hoc analyses were performed with the
Statistical Package for the Social Sciences (SPSS, v. 16.0, IBM).
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